Ocular Therapeutix Inc (NASDAQ:OCUL) shares, rose in value on Thursday, March 27, with the stock price up by 1.04% to the previous day’s close as strong demand from buyers drove the stock to $7.75.
Actively observing the price movement in the last trading, the stock closed the session at $7.67, falling within a range of $7.6501 and $8.04. The value of beta (5-year monthly) was 1.332. Referring to stock’s 52-week performance, its high was $11.77, and the low was $4.06. On the whole, OCUL has fluctuated by 11.67% over the past month.
With the market capitalization of Ocular Therapeutix Inc currently standing at about $1.23 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-02.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that OCUL’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of OCUL currently trading nearly 3.06% and 2.60% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.88, while the 7-day volatility ratio is showing 4.96% which for the 30-day chart, stands at 7.63%. Furthermore, Ocular Therapeutix Inc (OCUL)’s beta value is 1.49, and its average true range (ATR) is 0.47.
A comparison of Ocular Therapeutix Inc (OCUL) with its peers suggests the former has fared considerably weaker in the market. OCUL showed an intraday change of 1.04% in last session, and over the past year, it shrunk by -17.64%%.
Data on historical trading for Ocular Therapeutix Inc (NASDAQ:OCUL) indicates that the trading volumes over the past 10 days have averaged 1.61 and over the past 3 months, they’ve averaged 1.22 million. According to company’s latest data on outstanding shares, there are 157.75 million shares outstanding.
Nearly 15.79% of Ocular Therapeutix Inc’s shares belong to company insiders and institutional investors own 72.52% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.83 million shares as on 2025-03-14, resulting in a short ratio of 8.44. According to the data, the short interest in Ocular Therapeutix Inc (OCUL) stood at 810.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 11.6 million. The stock has fallen by -9.25% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the OCUL stock heading into the next quarter.
